Momordica charantia for type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Momordica charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control. OBJECTIVES: To assess the effects of mormodica charantia for type 2 diabetes mellitus. SEARCH METHODS: Several electronic databases were searched, among these were The Cochrane Library (Issue 1, 2012), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined with handsearches. No language restriction was used. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared momordica charantia with placebo or a control intervention, with or without pharmacological or non-pharmacological interventions. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data. Risk of bias of the trials was evaluated using the parameters of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of momordica charantia used in the interventions (no similar preparation was tested twice). MAIN RESULTS: Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria. Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high. Two RCTs compared the effects of preparations from different parts of the momordica charantia plant with placebo on glycaemic control in type 2 diabetes mellitus. There was no statistically significant difference in the glycaemic control with momordica charantia preparations compared to placebo. When momordica charantia was compared to metformin or glibenclamide, there was also no significant change in reliable parameters of glycaemic control. No serious adverse effects were reported in any trial. No trial investigated death from any cause, morbidity, health-related quality of life or costs. AUTHORS' CONCLUSIONS: There is insufficient evidence on the effects of momordica charantia for type 2 diabetes mellitus. Further studies are therefore required to address the issues of standardization and the quality control of preparations. For medical nutritional therapy, further observational trials evaluating the effects of momordica charantia are needed before RCTs are established to guide any recommendations in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehm, J., Murray, C. J. L., & Ezzati, M. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000058 · Cited by 2,860
Medicinal plants of India with anti-diabetic potential
Grover, J. K., Yadav, S., & Vats, V. (2002) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(02)00059-4 · Cited by 1,798
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766
The burden and costs of chronic diseases in low-income and middle-income countries.
Abegunde, D. O., Mathers, C. D., Adam, T., Ortegon, M., & Strong, K. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61696-1 · Cited by 1,603
Egger, M., Jüni, P., Bartlett, C., Holenstein, F., & Sterne, J. (2003) · Health Technology Assessment · doi:10.3310/hta7010 · Cited by 1,181
Investigating and Dealing with Publication and Other Biases
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch11 · Cited by 449
The burden and treatment of diabetes in elderly individuals in the U.S
Selvin, E., Coresh, J., & Brancati, F. L. (2006) · Diabetes Care · doi:10.2337/dc06-1058 · Cited by 261
Disability trends among elderly persons and implications for the future
Waidmann, T. A., & Liu, K. (2000) · The Journals of Gerontology Series B: Psychological Sciences and Social Sciences · doi:10.1093/geronb/55.5.s298 · Cited by 212
Cited by
Natural Products for the Treatment of Type 2 Diabetes Mellitus
Ríos, J., Francini, F., & Schinella, G. (2015) · Planta Medica · doi:10.1055/s-0035-1546131 · Cited by 446
Phytotherapy in the management of diabetes: A review
Governa, P., Baini, G., Borgonetti, V., Cettolin, G., Giachetti, D., Magnano, A., Miraldi, E., & Biagi, M. (2018) · Molecules · doi:10.3390/molecules23010105 · Cited by 182
Alam, M. A., Uddin, R., Subhan, N., Rahman, M. M., Jain, P., & Reza, H. M. (2015) · Journal of Lipids · doi:10.1155/2015/496169 · Cited by 123
“Almost all authors reported no serious side effects during the study period [152].”
BackgroundPeter, E. L., Kasali, F. M., Deyno, S., Mtewa, A., Nagendrappa, P. B., Tolo, C. U., Ogwang, P. E., & Sesaazi, D. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.10.033 · Cited by 96
Geck, M. S., Cristians, S., Berger-González, M., Casu, L., Heinrich, M., & Leonti, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01160 · Cited by 74
Metadata
- Authors
- Ooi, C. P., Yassin, Z., & Hamid, T.-A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2012-08-15
- Volume
- 2013
- Issue
- 12
- Pages
- CD007845-CD007845
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1874604737
- Cited by
- 96
- References
- 8
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Momordica charantia for type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1002/14651858.cd007845.pub3
- The paper
- Ooi, C. P., Yassin, Z., & Hamid, T.-A. (2012). Momordica charantia for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd007845.pub3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.